Braveheart Bio (NASDAQ:BRVE) Director David Charles Lubner Buys 55,555 Shares of Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) Director David Charles Lubner purchased 55,555 shares of the stock in a transaction dated Friday, August 7th. The shares were bought at an average price of $18.00 per share, for a total transaction of $999,990.00. Following the completion of the acquisition, the director owned 55,555 shares in the company, valued at $999,990. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Braveheart Bio Stock Up 0.7%

NASDAQ BRVE opened at $30.00 on Friday. Braveheart Bio, Inc. has a 1-year low of $28.47 and a 1-year high of $32.00.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.